Founded in 2000 and headquartered in Berkeley, California, Aduro Biotech Inc focuses on immunotherapy and uses technologies such as Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) to activate the intracellular STING receptor and bind to BCMA and TACI receptors, respectively. The company's therapies aim to treat patients with challenging diseases by harnessing the body's natural immune system.